Patents by Inventor Michael A. Kinch

Michael A. Kinch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060088541
    Abstract: The present invention is directed to compounds and methods for the treatment of cancer. The compounds of this invention have specificity for EphA2, an epithelial cell tyrosine kinase that is overexpressed in metastatic tumor cells. The compounds used in accordance with this invention may be provided in a pharmaceutical composition for treatment of metastatic cancer.
    Type: Application
    Filed: December 8, 2005
    Publication date: April 27, 2006
    Applicant: Purdue Research Foundation
    Inventors: Michael Kinch, Nicole Zantek, Patrick Hein
  • Publication number: 20060019899
    Abstract: EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.
    Type: Application
    Filed: September 23, 2005
    Publication date: January 26, 2006
    Applicants: University of Pittsburgh, Medimmune, Inc.
    Inventors: Walter Storkus, Michael Kinch
  • Publication number: 20050281783
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly metastatic cancer and cancers of T cell origin, and hyperproliferative diseases involving EphA2-expressing cells. The methods of the invention entail the use of a Listeria-based EphA2 vaccine. The invention also provides pharmaceutical compositions comprising one or more Listeria-based vaccines of the invention either alone or in combination with one or more other agents useful for cancer therapy. In certain aspects of the invention, the methods entail eliciting both CD4+ and CD8+ T-cell responses against EphA2 and/or EphA2-expressing cells.
    Type: Application
    Filed: October 15, 2004
    Publication date: December 22, 2005
    Inventors: Michael Kinch, Peter Kiener, Elizabeth Bruckheimer, Thomas Dubensky, David Cook
  • Publication number: 20050175616
    Abstract: The present invention relates to the use of antitumor compositions capable of inhibiting PCDGF biological activity for the treatment of cancers. In particular the present invention relates to the use of PCDGF antagonist, e.g., antibodies that prevent PCDGF from binding its receptor, Rse (also referred to as “Sky” and “Tyro3”).
    Type: Application
    Filed: May 26, 2004
    Publication date: August 11, 2005
    Inventors: Peter Kiener, Solomon Langermann, Michael Kinch, Elizabeth Bruckheimer
  • Publication number: 20050169931
    Abstract: The present invention is directed to compounds and methods for the treatment of metastatic disease. The compounds of this invention have specificity for EphA2, an epithelial cell tyrosine kinase that is overexpressed in metastatic tumor-cells. The compounds used in accordance with this invention may be provided in a pharmaceutical composition for treatment of metastatic disease.
    Type: Application
    Filed: February 22, 2005
    Publication date: August 4, 2005
    Applicant: Purdue Research Foundation
    Inventors: Michael Kinch, Nicole Zantek, Patrick Hein
  • Publication number: 20050153923
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of a hyperproliferative cell disease, particularly cancer. The methods of the invention comprise the administration of an effective amount of a composition that targets cells expressing an Eph family receptor tyrosine kinase, such as EphA2 or EphA4, for the treatment, management, or prevention of hyperproliferative diseases, particularly cancer. In one embodiment, the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety attached to a delivery vehicle, and one or more therapeutic or prophylactic agents that treat or prevent a hyperproliferative disease, where the therapeutic or prophylactic agents are operatively associated with the delivery vehicle.
    Type: Application
    Filed: December 3, 2004
    Publication date: July 14, 2005
    Inventor: Michael Kinch
  • Publication number: 20050152899
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels in cells which EphA2 has been agonized. The invention also encompasses antibodies that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
    Type: Application
    Filed: November 19, 2004
    Publication date: July 14, 2005
    Inventors: Michael Kinch, Kelly Carles-Kinch, Jane Stewart
  • Publication number: 20050147593
    Abstract: The present invention relates to methods and compositions designed for treatment, management, or prevention of a hyperproliferative cell disease, particular cancer. The methods of the invention comprise the administration of an effective amount of a composition that targets cells expressing low molecular weight protein tyrosine kinase (“LMW-PTP”) in particular using moieties that bind an Eph family receptor tyrosine kinase, such as EphA2 or EphA4, and inhibits or reduces LMW-PTP expression and/or activity. In one embodiment, the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety attached to a delivery vehicle, and one or more agents that inhibit LMW-PTP expression and/or activity operatively associated with the delivery vehicle.
    Type: Application
    Filed: December 3, 2004
    Publication date: July 7, 2005
    Inventor: Michael Kinch
  • Publication number: 20050059592
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of a non-neoplastic hyperproliferative cell or excessive cell accumulation disorders, particularly those involving hyperproliferation of epithelial or endothelial cells. In one embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and increase EphA2 cytoplasmic tail phosphorylation and/or increase EphA2 autophosphorylation in cells which EphA2 has been agonized. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and reduce EphA2 activity (other than autophosphorylation). In another embodiment, the methods of the invention comprise administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and decrease a pathology-causing cell phenotype (e.g.
    Type: Application
    Filed: April 12, 2004
    Publication date: March 17, 2005
    Inventors: Peter Kiener, Michael Kinch, Solomon Langermann, Jennifer Reed
  • Publication number: 20050049176
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of a hypoproliferative cell disorder, especially those disorders relating to the destruction, shedding, or inadequate proliferation of epithelial and/or endothelial cells, particularly interstitial cystitis (IC) and lesions associated with inflammatory bowel disease (IBD). The methods of the invention comprise the administration of an effective amount of one or more agents that are antagonists of EphA2.
    Type: Application
    Filed: April 12, 2004
    Publication date: March 3, 2005
    Inventors: Peter Kiener, Michael Kinch, Solomon Langermann
  • Publication number: 20050048550
    Abstract: EphA2 T-cell epitope agonists are provided herein. The agonists include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitope agonists are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The agonists also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 agonists also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.
    Type: Application
    Filed: July 22, 2004
    Publication date: March 3, 2005
    Applicants: University of Pittsburgh-of the Commonwealth System of Higher Education, Medimmune, Inc.
    Inventors: Walter Storkus, Michael Kinch
  • Publication number: 20050013819
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. In one embodiment, the methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to EphA4 and agonize EphA4. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to EphA4 and inhibit cancer cell colony formation in soft agar or tubular network formation in three-dimensional basement membrane or extracellular matrix preparation. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more antibodies that preferentially binds to an EphA4 epitope that is exposed on cancer cells but not non-cancer cells.
    Type: Application
    Filed: June 7, 2004
    Publication date: January 20, 2005
    Inventors: Michael Kinch, Kelly Carles-Kinch
  • Patent number: 5534719
    Abstract: Group II-VI thin film transistors, a method of making same and a monolithic device containing a detector array as well as transistors coupled thereto wherein, according to a first embodiment, there is provided a group II-VI insulating substrate, a doped layer of a group II-VI semiconductor material disposed over the substrate, an insulating gate region disposed over the doped layer, a pair of spaced contacts on the doped layer providing source and drain contacts, a gate contact disposed over the insulating gate region, an insulating layer disposed over exposed regions of the substrate, doped layer, insulating gate region and contacts and metallization disposed on the insulating layer and extending through the insulating layer to the contacts. The thickness of the doped layer is less than the maximum depletion region thickness thereof.
    Type: Grant
    Filed: January 27, 1995
    Date of Patent: July 9, 1996
    Assignee: Texas Instruments Incorporated
    Inventors: Richard A. Schiebel, Michael A. Kinch, Roland J. Koestner
  • Patent number: 5403760
    Abstract: Group II-VI thin film transistors, a method of making same and a monolithic device containing a detector array as well as transistors coupled thereto wherein, according to a first embodiment, there is provided a group II-VI insulating substrate, a doped layer of a group II-VI semiconductor material disposed over the substrate, an insulating gate region disposed over the doped layer, a pair of spaced contacts on the doped layer providing source and drain contacts, a gate contact disposed over the insulating gate region, an insulating layer disposed over exposed regions of the substrate, doped layer, insulating gate region and contacts and metallization disposed on the insulating layer and extending through the insulating layer to the contacts. The thickness of the doped layer is less than the maximum depletion region thickness thereof.
    Type: Grant
    Filed: November 15, 1993
    Date of Patent: April 4, 1995
    Assignee: Texas Instruments Incorporated
    Inventors: Richard A. Schiebel, Michael A. Kinch, Roland J. Koestner
  • Patent number: 5144138
    Abstract: Photocapacitive detectors with varying bandgap Hg.sub.1-x Cd.sub.x Te (604) for two color detection and one color detection with increased potential well capacity. Preferred embodiments include a transparent insulated gate (608) on a top layer (632) of Hg.sub.0.8 Cd.sub.0.2 Te over a lower layer (634) of Hg.sub.0.83 Cd.sub.0.27 Te for detection of two infrared colors by varying gate potential to either confine the potential well to the top layer or to extend the potential well to both layers. Also, methods of compositionally grading the Hg.sub.1-x Cd.sub.x Te by fluid transport plus diffusion.
    Type: Grant
    Filed: October 6, 1989
    Date of Patent: September 1, 1992
    Assignee: Texas Instruments Incorporated
    Inventors: Michael A. Kinch, C. Grady Roberts
  • Patent number: 5043293
    Abstract: The disclosure relates to oxide-semiconductor interfaces which are grown with varying amounts of fixed positive (or negative) charge. The invention utilizes these different values to form a channel stop for a charge transfer device. For HgCdTe two different oxides are used, namely, those produced by wet anodization (having large values of fixed positive charge) and plasma oxidation (having low values of fixed charge). The voltage range of operation of the active gate is determined by the difference in fixed positive charge for these regions and the insulator thicknesses.
    Type: Grant
    Filed: June 1, 1990
    Date of Patent: August 27, 1991
    Assignee: Texas Instruments Incorporated
    Inventors: Michael A. Kinch, Arturo Simmons
  • Patent number: 4630090
    Abstract: The disclosure relates to a stepped insulator process for HgCdTe infared focal plane devices, the insulator being a combination of two insulator materials, ZnS and SiO, which differ in dielectric constant and chemical reactivity. The structure is patterned on HgCdTe which has an accumulated surface region. The resulting configuration significantly reduces pin hole short circuits introduced during via etching and improves the operating range (channel stopping action) for a given step height over that of ZnS alone.
    Type: Grant
    Filed: September 25, 1984
    Date of Patent: December 16, 1986
    Assignee: Texas Instruments Incorporated
    Inventors: Arturo Simmons, Michael A. Kinch
  • Patent number: 4507160
    Abstract: The disclosure relates to a method for reducing impurity concentration in mercury cadmium telluride alloys wherein impurities are attracted to a region saturated with second phase tellurium during annealing in a saturated mercury atmosphere where the second phase tellurium and the impurities attracted thereto can be removed by polishing, etching, grinding, or the like.
    Type: Grant
    Filed: December 23, 1983
    Date of Patent: March 26, 1985
    Assignee: Texas Instruments Incorporated
    Inventors: Jeffrey D. Beck, Herbert F. Schaake, John H. Tregilgas, Michael A. Kinch
  • Patent number: 4501625
    Abstract: The disclosure relates to a method for making extrinsically doped HgCdTe alloys containing Cu, Ag, or Au or other dopant impurity whereby the excess tellurium in the core is annihilated (stoichiometrically compensated by excess in-diffusing Hg) and the dopant impurities are then permitted to randomly move through the slab to provide for homogeneity thereof. A post-annealing step of much greater than normal temperature-time length than was provided in the prior art is used. A standard post-annealing step in a saturated mercury vapor atomosphere leaves second phase tellurium (and gettered impurities) at the center of the slab, and longer term post-annealing negates this situation by annihilating the second phase tellurium in the slab and thus permitting the impurities to randomly travel by solid state diffusion throughout the slab to ultimately be distributed therein in a homogeneous manner.
    Type: Grant
    Filed: December 23, 1983
    Date of Patent: February 26, 1985
    Assignee: Texas Instruments Incorporated
    Inventors: John H. Tregilgas, Jeffrey D. Beck, Michael A. Kinch, Herbert F. Schaake
  • Patent number: 4377904
    Abstract: A monolithic charge-coupled infrared imaging device (CCIRID) is fabricated on N-type HgCdTe. A native oxide layer on the semiconductor is used, in combination with ZnS to provide first level insulation. An opaque field plate over first level insulation is provided for signal channel definition. Second level insulation (ZnS) is substantially thicker than the first level, and is provided with a stepped or sloped geometry under the first level gates. Input and output diodes are provided with MIS guard rings to increase breakdown voltages.
    Type: Grant
    Filed: September 9, 1980
    Date of Patent: March 29, 1983
    Assignee: Texas Instruments Incorporated
    Inventors: Richard A. Chapman, Dennis D. Buss, Michael A. Kinch